Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Prevalence of HIV-TB co-infection and impact of HIV infection on pulmonary tuberculosis outcome in Togo
Bulletin de la Societe de Pathologie Exotique, Volume 104, No. 5, Year 2011
Notification
URL copied to clipboard!
Description
The aim of this study was to determine the prevalence of HIV infection in tuberculosis patients and its impact on the TB treatment. We enrolled 569 pulmonary TB patients in four diagnosis and treatment centres in Togo. All patients were new TB cases and received the first-line TB drugs: two months of rifampicinpyrazinamide-isoniazid-ethambutol and six months of isoniazid-ethambutol. HIV testing was done according to the national guidelines, using rapid diagnosis tests. The CD4 lymphocyte counting was performed by Facscalibur (BD, Sciences) for all HIV-positive patients. Of the 569 TB patients enrolled, 135 (23.7%) were HIV positive (TB/HIV+). HIV prevalence was 22.4% (76 of 339) among men and 25.6% (59 of 230) among women without statistical difference. The global rate of treatment success was 82.2%. The rate of treatment success was lower (64.3%) in TB/HIV+ patients than in TB/HIV- patients (87.5%) (p <0.01). The mortality rates were 25.6% and 11.8% in TB/HIV+ patients and TB/HIV- patients, respectively, with a statistically significant difference (p <0.01). We did not found any statistical difference between the rates of treatment success among TB/HIV- (87.5%) patients and TB/HIV+ patients who had TCD4 lymphocyte counts above 200/μl (84.4%). TB program in Togo must take into account HIV infection to improve its performance. © Société de pathologie exotique et Springer-Verlag France 2010.
Authors & Co-Authors
Dagnra, Anoumou Yaotsé
Togo, Lome
Prog. Natl. Lutte Contre la Cecite
Adjoh, Komi Seraphin
Togo, Lome
Centre Hospitalier Universitaire Tokoin
Togo
Programme National Lèpre-tuberculose
Tchaptchet Heunda, S.
Togo, Lome
Prog. Natl. Lutte Contre la Cecite
Patassi, Akouda Akessiwe
Togo, Lome
Centre Hospitalier Universitaire Tokoin
Sadzo Hetsu, D.
Togo
Programme National Lèpre-tuberculose
Awokou, Fantché
Togo
Programme National Lèpre-tuberculose
Tidjani, Osseni
Togo, Lome
Centre Hospitalier Universitaire Tokoin
Statistics
Citations: 39
Authors: 7
Affiliations: 3
Identifiers
Doi:
10.1007/s13149-010-0079-3
ISSN:
00379085
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Togo
Participants Gender
Male
Female